BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab
This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.
Authors
- Michael Sy (ORCID: https://orcid.org/0000-0003-4826-0066)
- Anastasia Chumakova (ORCID: https://orcid.org/0000-0002-5602-578X)
- Victoria Fleming
- Lauren McKay
- Michael Demetriou (ORCID: https://orcid.org/0000-0001-8547-5774)
Institutions
- University of California, Irvine (US)
Publication Details
- Journal
- Journal of Neuroinflammation
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12974-025-03632-y
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39